<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Гинекология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2079-5696</issn><issn publication-format="electronic">2079-5831</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">88599</article-id><article-id pub-id-type="doi">10.26442/20795696.2021.5.201058</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНАЯ СТАТЬЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">The concomitant estrogen-dependent diseases and the ovarian reserve condition for patients with severe peritoneal endometriosis, included in the vitro fertilization programmes</article-title><trans-title-group xml:lang="ru"><trans-title>Сопутствующие эстрогензависимые заболевания и состояние овариального резерва у включаемых в программы экстракорпорального оплодотворения пациенток с тяжелым перитонеальным эндометриозом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9327-0656</contrib-id><name-alternatives><name xml:lang="en"><surname>Ershova</surname><given-names>Irina Yu.</given-names></name><name xml:lang="ru"><surname>Ершова</surname><given-names>Ирина Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>канд. мед. наук, науч. сотр. отд-ния вспомогательных репродуктивных технологий, глав. врач</p></bio><email>i3236987@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1275-9220</contrib-id><name-alternatives><name xml:lang="en"><surname>Krasnopolskaya</surname><given-names>Ksenia V.</given-names></name><name xml:lang="ru"><surname>Краснопольская</surname><given-names>Ксения Владиславовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof., Corr. Memb. RAS</p></bio><bio xml:lang="ru"><p>чл.-кор. РАН, д-р мед. наук, проф., рук. отд-ния вспомогательных репродуктивных технологий, мед. рук.</p></bio><email>deti222@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5342-8129</contrib-id><name-alternatives><name xml:lang="en"><surname>Orazov</surname><given-names>Mekan R.</given-names></name><name xml:lang="ru"><surname>Оразов</surname><given-names>Мекан Рахимбердыевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф. каф. акушерства и гинекологии с курсом перинатологии Медицинского института</p></bio><email>omekan@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3895-8359</contrib-id><name-alternatives><name xml:lang="en"><surname>Lagutina</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Лагутина</surname><given-names>Елена Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Graduate Student</p></bio><bio xml:lang="ru"><p>аспирант каф. акушерства и гинекологии с курсом перинатологии Медицинского института</p></bio><email>Lagutina_e.v@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Moscow Regional Research Institute of Obstetrics and Gynecology</institution></aff><aff><institution xml:lang="ru">ГБУЗ МО «Московский областной научно-исследовательский институт акушерства и гинекологии»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Prior Clinic</institution></aff><aff><institution xml:lang="ru">ООО «ПРИОР КЛИНИКА» (Клиника репродуктивного здоровья “Prior Clinic”)</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">People’s Friendship University of Russia</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский университет дружбы народов»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-11-26" publication-format="electronic"><day>26</day><month>11</month><year>2021</year></pub-date><volume>23</volume><issue>5</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>386</fpage><lpage>391</lpage><history><date date-type="received" iso-8601-date="2021-11-17"><day>17</day><month>11</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-11-17"><day>17</day><month>11</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://gynecology.orscience.ru/2079-5831/article/view/88599">https://gynecology.orscience.ru/2079-5831/article/view/88599</self-uri><abstract xml:lang="en"><p><bold>Aim.</bold> Is specification of the nature and frequency of concomitant forms of genital endometriosis and other estrogen-dependent diseases (EDD) for the infertile women with severe peritoneal endometriosis (PE), as well as the assessment of the ovarian reserve condition for the patients of different ages.</p> <p><bold>Materials and methods.</bold> The total 142 infertile women with severe peritoneal endometriosis (III–IV stage of the external genital endometriosis according to the American Fertility Society classification) were examined at the age of 32.3±3.2 years (min–max = 23–40 years). The clinical status assessment was conducted, using a standard set of diagnostic procedures, prescribed for the inclusion of patients in the IVF program. The ovarian reserve was estimated by the level of the anti-Mullerian Hormone level determined by the immunoenzyme method.</p> <p><bold>Results. </bold>The concomitant 2-sided endometriotic ovarian cysts (96%), myoma (19.7%) and the adenomyosis (16.9%) were most common for the patients with severe peritoneal endometriosis. The severely reduced the anti-Mullerian Hormone rates (&lt;0.4 ng/ml) were much higher among patients &gt;35 years old (24.6% compared to 10.6% for younger patients; <italic>p</italic>=0.028).</p> <p><bold>Conclusion.</bold> The infertility for severe peritoneal endometriosis is supported by concomitant estrogen-dependent diseases, of which 2-sided endometriomas, adenomyosis and uterine myoma are of the most pathological.</p> <p>The low efficiency of IVF in the treatment of patients with severe peritoneal endometriosis and concomitant estrogen-dependent diseases is explained by the aggravation of the embryonic and endometrial factors for the infertility. The other reason that worsens the results of IVF for such patients is late reproductive age (&gt;35 years) that increases the observed reduction of the ovarian reserve.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель. </bold>Уточнить характер и частоту сопутствующих форм генитального эндометриоза и других эстрогензависимых заболеваний (ЭЗЗ) у инфертильных женщин с тяжелым перитонеальным эндометриозом (ПЭ), а также оценить состояние овариального резерва у пациенток разного возраста.</p> <p><bold>Материалы и методы. </bold>Обследованы 142 инфертильные женщины с тяжелым ПЭ (III–IV стадия распространения наружного генитального эндометриоза по классификации AFS) в возрасте 32,3±3,2 года (min–max = 23–40 лет). Оценку клинического статуса проводили с применением стандартного набора диагностических процедур, назначаемых при включении пациенток в программу экстракорпорального оплодотворения (ЭКО). Овариальный резерв оценивался по уровню антимюллерова гормона, определяемого иммуноферментным методом.</p> <p><bold>Результаты. </bold>С наибольшей частотой у пациенток с тяжелым ПЭ встречались сопутствующие двусторонние эндометриодные кисты яичников (96%), миома (19,7%) и аденомиоз (16,9%). Резко сниженные показатели антимюллерова гормона (&lt;0,4 нг/мл) обнаруживались значительно чаще среди больных &gt;35 лет (24,6% против 10,6% у более молодых пациенток, <italic>р</italic>=0,028).</p> <p><bold>Заключение. </bold>Бесплодие при тяжелом ПЭ поддерживается сопутствующими ЭЗЗ, из которых наибольшую патологическую значимость имеют двусторонние эндометриомы, аденомиоз и миома матки. Низкая эффективность ЭКО при лечении пациенток с тяжелым ПЭ и сопутствующими ЭЗЗ объясняется усугублением эмбрионального и эндометриального факторов бесплодия. Еще одной причиной, ухудшающей результаты ЭКО у таких больных, является поздний репродуктивный возраст (&gt;35 лет), утяжеляющий наблюдаемую редукцию овариального резерва.</p></trans-abstract><kwd-group xml:lang="en"><kwd>infertility</kwd><kwd>peritoneal endometriosis</kwd><kwd>ovarian reserve</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>бесплодие</kwd><kwd>перитонеальный эндометриоз</kwd><kwd>овариальный резерв</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Barnett R, Banks N, Decherney AH. Endometriosis and Fertility Preservation. Clin Obstet Gynecol. 2017;60(3):517-23. DOI:10.1097/GRF.0000000000000311</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Carrillo L, Seidman DS, Cittadini E, Meirow D. The role of fertility preservation in patients with endometriosis. J Assist Reprod Genet. 2016;33(3):317-23. DOI:10.1007/s10815-016-0646-z</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Llarena NC, Falcone T, Flyckt RL. Fertility preservation in women with endometriosis. Clin Med Insights Reprod Health. 2019;13:1179558119873386. DOI:10.1177/1179558119873386</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Macer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. Obstet Gynecol Clin North Am. 2012;39(4):535-49. DOI:10.1016/j.ogc.2012.10.002</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Cranney R, Condous G, Reid S. An update on the diagnosis, surgical management, and fertility outcomes for women with endometrioma. Acta Obstet Gynecol Scand. 2017;96(6):633-43. DOI:10.1111/aogs.13114</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Bulun SE, Monsivais D, Kakinuma T, et al. Molecular biology of endometriosis: from aromatase to genomic abnormalities. Semin Reprod Med. 2015;33(3):220-4. DOI:10.1055/s-0035-1554053</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Marquardt RM, Kim TH, Shin JH, Jeong JW. Progesterone and Estrogen Signaling in the Endometrium: What Goes Wrong in Endometriosis? Int J Mol Sci. 2019;20(15):3822. DOI:10.3390/ijms20153822</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Краснопольская К.В., Назаренко Т.А. Клинические аспекты лечения бесплодия в браке. Диагностические и терапевтические программы с использованием методов восстановления естественной фертильности и вспомогательных репродуктивных технологий: руководство. М: ГЭОТАР-Медиа, 2013 [Krasnopolskaia KV, Nazarenko TA. Clinical aspects of the treatment of infertility in marriage. Diagnostic and therapeutic programs using natural fertility restoration and assisted reproductive technologies: a guide. Moscow: GEOTAR-Media, 2013 (in Russian)].</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. Am J Obstet Gynecol. 2017;217(2):129-40. DOI:10.1016/j.ajog.2017.02.027</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Johnstone EB, Link MH. Controversies in the Management of Endometrioma To Cure Sometimes, to Treat Often, to Comfort Always? Clin Obstet Gynecol. 2015;58(4):754-64. DOI:10.1097/GRF.0000000000000151</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Kodaman PH. Current strategies for endometriosis management. Obstet Gynecol Clin North Am. 2015;42(1):87-101. DOI:10.1016/j.ogc.2014.10.005</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Somigliana E, Vigano P, Benaglia L, et al. Management of Endometriosis in the Infertile Patient. Semin Reprod Med. 2017;35(1):31-7. DOI:10.1055/s-0036-1597125</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Benaglia L, Castiglioni M, Paffoni A, et al. Is endometrioma-associated damage to ovarian reserve progressive? Insights from IVF cycles. Hum Reprod Update. 2015;21(4):486-99. DOI:10.1093/humupd/dmv012</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Kasapoglu I, Ata B, Uyaniklar O, et al. Endometrioma-related reduction of ovarian reserve (ERROR): a prospective longitudinal study. Fertil Steril. 2018;110(1):122-7. DOI:10.1016/j.fertnstert.2018.03.015</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Younis JS, Shapso N, Fleming R, et al. Impact of unilateral versus bilateral ovarian endometriotic cystectomy on ovarian reserve: a systematic review and meta-analysis. Hum Reprod Update. 2019;25(3):375-91. DOI:10.1093/humupd/dmy049</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Ferrero S, Scala C, Tafi E, et al. Impact of large ovarian endometriomas on the response to superovulation for in vitro fertilization: a retrospective study. Eur J Obstet Gynecol Reprod Biol. 2017;213:17-21. DOI:10.1016/j.ejogrb.2017.04.003</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Kitajima M, Khan KN, Harada A, et al. Association between ovarian endometrioma and ovarian reserve. Front Biosci (Elite Ed). 2018;10:92-102. DOI:10.2741/e810</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Maggiore LRU, Gupta JK, Ferrero S. Treatment of endometrioma for improving fertility. Eur J Obstet Gynecol Reprod Biol. 2017;209:81-5. DOI:10.1016/j.ejogrb.2016.02.035</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Park HJ, Kim H, Lee GH, et al. Could surgical management improve the IVF outcomes in infertile women with endometriomas. A review. Obstet Gynecol Sci. 2019;62(1):1-10. DOI:10.5468/ogs.2019.62.1.1</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Vignali M, Mabrouk M, Ciocca E, et al. Surgical excision of ovarian endometriomas: Does it truly impair ovarian reserve? Long term anti-Müllerian hormone (AMH) changes after surgery. J Obstet Gynaecol Res. 2015;41(11):1773-8. DOI:10.1111/jog.12830</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Goodman LR, Golberg JM, Flyckt RL, et al. Effect of surgery on ovarian reserve in women with endometriomas, endometriosis and controls. Am J Obstet Gynecol. 2016;215(5):589.e1-589.e6. DOI:10.1016/j.ajog.2016.05.029</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Dueholm M. Uterine adenomyosis and infertility, review of reproductive outcome after in vitro fertilization and surgery. Acta Obstet Gynecol Scand. 2017;96(6):715-26. DOI:10.1111/aogs.13158</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Vercellini P, Bonfanti I, Berlanda N. Adenomyosis and infertility: is there a causal link? Expert Rev Endocrinol Metab. 2019;14(6):365-7. DOI:10.1080/17446651.2019.1697675</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Vlahos NF, Theodoridis TD, Partsinevelos GA. Myomas and Adenomyosis: Impact on Reproductive Outcome. Biomed Res Int. 2017;2017:5926470. DOI:10.1155/2017/5926470</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Zepiridis LI, Grimbizis GF, Tarlatzis BC. Infertility and uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2016;34:66-73. DOI:10.1016/j.bpobgyn.2015.12.001</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Rothenberger NJ, Somasundaram A, Stabile LP. The Role of the Estrogen Pathway in the Tumor Microenvironment. Int J Mol Sci. 2018;19(2):611. DOI:10.3390/ijms19020611</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Liang J, Shang Y. Estrogen and cancer. Annu Rev Physiol. 2013;75:225-40. DOI:10.1146/annurev-physiol-030212-183708</mixed-citation></ref></ref-list></back></article>
